{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033071","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.840284+00:00","generated_at":"2026-05-25T10:54:19.102109+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TScan Q4 net loss $35.8M; revenue down 90% YoY; heme relapse data positive","bullets":["Net loss $35.8M in Q4 vs $19.6M YoY; full-year net loss $127.5M vs $89.2M.","Revenue $0.7M Q4 vs $7.2M YoY; full-year $2.8M vs $21.0M, due to Amgen collaboration timing.","Cash, equivalents and marketable securities $290.1M; funding into Q1 2027.","ASH heme trial: 2/26 (8%) relapsed vs 4/12 (33%) control; HR 0.30.","IND cleared for MAGE-A4 TCR-T; closed $30M registered direct offering at 37% premium."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033071","json":"https://secwatch.observer/filing/0000950170-25-033071.json","markdown":"https://secwatch.observer/filing/0000950170-25-033071.md","text":"https://secwatch.observer/filing/0000950170-25-033071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025033071/0000950170-25-033071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025033071/tcrx-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T10:54:19.102109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}